Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 36 articles: HTML format

Single Articles

August 2024
1. WU H, Sun C, Cao W, Teng Q, et al
   Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
   Cancer Lett. 2024;602:217192.
   PubMed     Abstract available
   
   
   July 2024
2. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
   The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
   Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
   PubMed     Abstract available
   
   
   
3. XU J, Lu W, Wei X, Zhang B, et al
   Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
   Cancer Lett. 2024;593:216928.
   PubMed     Abstract available
   
   
   June 2024
4. FENG X, Ji Z, Fan X, Kong Y, et al
   ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
   Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
   PubMed     Abstract available
   
   
   
5. MENG H, Miao H, Zhang Y, Chen T, et al
   YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
   Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
   PubMed     Abstract available
   
   
   
6. YU Y, Lyu C, Li X, Yang L, et al
   Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
   Cancer Lett. 2024;596:217022.
   PubMed     Abstract available
   
   
   April 2024
7. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
   Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
   Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
   PubMed     Abstract available
   
   
   
8. KAUR P, Shankar E, Gupta S
   EZH2-mediated development of therapeutic resistance in cancer.
   Cancer Lett. 2024;586:216706.
   PubMed     Abstract available
   
   
   March 2024
9. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
   Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
   Cancer Lett. 2024;585:216673.
   PubMed     Abstract available
   
   
   February 2024
10. LIU J, Liu C, Ma Y, Pan X, et al
    STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).
    Cancer Lett. 2024 Feb 17:216700. doi: 10.1016/j.canlet.2024.216700.
    PubMed     Abstract available
    
    
    November 2023
11. GARG V, Kumar L
    Metronomic chemotherapy in ovarian cancer.
    Cancer Lett. 2023 Nov 1:216469. doi: 10.1016/j.canlet.2023.216469.
    PubMed     Abstract available
    
    
    October 2023
12. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
    Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
    Cancer Lett. 2023 Oct 12:216437. doi: 10.1016/j.canlet.2023.216437.
    PubMed     Abstract available
    
    
    September 2023
13. VENKATA PP, Jayamohan S, He Y, Alejo S, et al
    Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
    Cancer Lett. 2023 Sep 13:216383. doi: 10.1016/j.canlet.2023.216383.
    PubMed     Abstract available
    
    
    August 2023
14. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    PubMed     Abstract available
    
    
    July 2023
15. CHEN X, Zhou J, Li X, Wang X, et al
    Corrigendum to "Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype" [Cancer Lett. 435 (28 October 2018) 80-91].
    Cancer Lett. 2023 Jul 8:216292. doi: 10.1016/j.canlet.2023.216292.
    PubMed    
    
    
    May 2023
16. SHAO Y, Li H, Wu Y, Wang X, et al
    The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer.
    Cancer Lett. 2023;565:216241.
    PubMed     Abstract available
    
    
    April 2023
17. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
    Cancer Lett. 2023;563:216196.
    PubMed    
    
    
    January 2023
18. ZHANG Y, Qiu JG, Jia XY, Ke Y, et al
    METTL3-mediated N6-methyladenosine modification and HDAC5/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance.
    Cancer Lett. 2023;553:215971.
    PubMed     Abstract available
    
    
    
19. HOLLIS RL
    Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
    Cancer Lett. 2023;555:216057.
    PubMed     Abstract available
    
    
    June 2022
20. RUSSO A, Zizhao Y, Heyrman GM, Cain BP, et al
    Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
    Cancer Lett. 2022 Jun 10:215779. doi: 10.1016/j.canlet.2022.215779.
    PubMed     Abstract available
    
    
    May 2022
21. WANG W, Jo H, Park S, Kim H, et al
    Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer.
    Cancer Lett. 2022 May 12:215735. doi: 10.1016/j.canlet.2022.215735.
    PubMed     Abstract available
    
    
    April 2022
22. ZHAO Z, Shuang T, Gao Y, Lu F, et al
    Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization.
    Cancer Lett. 2022;530:45-58.
    PubMed     Abstract available
    
    
    January 2022
23. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    PubMed     Abstract available
    
    
    
24. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    PubMed     Abstract available
    
    
    December 2021
25. QIAO HY, Zhang Q, Wang JM, Jiang JY, et al
    TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
    Cancer Lett. 2021;529:85-99.
    PubMed     Abstract available
    
    
    
26. LIU C, Huang Y, Qin T, You L, et al
    AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
    Cancer Lett. 2021 Dec 20. pii: S0304-3835(21)00638.
    PubMed     Abstract available
    
    
    November 2021
27. PIN F, Prideaux M, Huot JR, Essex AL, et al
    Non-bone metastatic cancers promote osteocyte-induced bone destruction.
    Cancer Lett. 2021;520:80-90.
    PubMed     Abstract available
    
    
    September 2021
28. PI R, Yang Y, Hu X, Li H, et al
    Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00464.
    PubMed     Abstract available
    
    
    August 2021
29. YAMAWAKI K, Mori Y, Sakai H, Kanda Y, et al
    Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance.
    Cancer Lett. 2021;521:29-38.
    PubMed     Abstract available
    
    
    
30. YOON MJ, Cha H, Ahn J, Lee D, et al
    Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells.
    Cancer Lett. 2021;520:267-280.
    PubMed     Abstract available
    
    
    February 2021
31. LUO Q, Wu X, Zhang Y, Shu T, et al
    Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
    Cancer Lett. 2021;498:243.
    PubMed    
    
    
    January 2021
32. LIU Y, Yang J, Shi Z, Tan X, et al
    In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.
    Cancer Lett. 2021 Jan 29. pii: S0304-3835(21)00048.
    PubMed     Abstract available
    
    
    
33. BHARDWAJ V, Tan YQ, Wu MM, Ma L, et al
    Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Cancer Lett. 2021 Jan 8. pii: S0304-3835(21)00010.
    PubMed     Abstract available
    
    
    December 2020
34. BUNGSY M, Palmer MCL, Jeusset LM, Neudorf NM, et al
    Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Cancer Lett. 2020 Dec 5. pii: S0304-3835(20)30649.
    PubMed     Abstract available
    
    
    November 2020
35. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Cancer Lett. 2020 Nov 19. pii: S0304-3835(20)30603.
    PubMed     Abstract available
    
    
    June 2020
36. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.